Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Technical Review: New Releases from Drug Maker Majors Cushion Against Patent Cliff Effects



 Technical Review: New Releases from Drug Maker Majors Cushion Against Patent
                                Cliff Effects

  PR Newswire

  LONDON, January 16, 2013

LONDON, January 16, 2013 /PRNewswire/ --

All companies mentioned in the release below have received technical review as
of the close of yesterday's session. These reports are available for free at
http://www.stockcall.com/register

For many major drug manufacturers, including Pfizer Inc. ^(1) (NYSE: PFE ) and
Merck & Co. Inc. ^(2) (NYSE: MRK), the so-called "patent cliff" put a major
dent in sales and profits. The loss of exclusivity of many blockbuster drugs
allowed generics to be made, and major drug companies have been left to
compete with generic versions that are, in most cases, cheaper.

One of the historically best-selling drug which went off-patent in November
2011 is Lipitor. The anti-cholesterol drug was Pfizer's golden goose as it
earned the company close to $9.6 billion in revenue in 2011. Merck & Co. also
suffered from patent loss with some of its blockbuster drugs such as
Singulair, Maxalt, Cozaar/Hyzaar fell off the patent cliff. But these
companies have learnt to survive. Register with us today and access the
technical report in Merck & Co. at

http://www.StockCall.com/MRK011613.pdf

While several brand-name drug companies have come out with their own generic
equivalents, sales have still suffered. Successful marketing abroad has also
helped to boost sales for select companies; however; numbers are still down
from exclusivity highs. Depressed sales for some could be set to rebound
though, as companies are succeeding in bringing a slew of exciting, new
products to market.

A number of major drug manufacturers are currently focusing their attention on
and receiving FDA or European Commission approval, which if granted creates
the potential for big returns. Pfizer recently announced that the European
Commission gave its approval to expand the company's pneumococcal conjugate
vaccine, Prevenar 13 to children and adolescents between the ages of 6 to 17
years. The vaccine is for active immunization for the prevention of invasive
disease, pneumonia and acute otitis media caused by vaccine-type 
Streptococcus pneumoniae .

Additionally, industry players are developing treatments and diagnostic
methods for a number of conditions, including cancer, Pneumonia,
cardiovascular diseases and Alzheimer's among others. With a number of these
products newly on the market, it will be interesting to see which, if any,
become the next big bread winners for major drug manufacturers.  

Footer:

 1. Pfizer Inc. Technical Analysis [ http://www.StockCall.com/PFE011613.pdf ]
     
 2. Merck & Co. Inc. Technical Analysis [
    http://www.StockCall.com/MRK011613.pdf ]  

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at

http://www.stockcall.com  

Contact: Contact Person: William T. Knight, Email: info@stockcall.com, Contact
Number: +1(646)396-9857 (9:00 am EST - 01:30 pm EST)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement